



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/799,514-Conf. #8487	
			Filing Date	March 12, 2004	
			First Named Inventor	Francois Spertini	
			Art Unit	1644	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	3	Attorney Docket Number	30985/41486

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
NR	A1*	US-5,767,075	06-16-1998	Avruch <i>et al.</i>	
NR	A2*	US-6,042,831	03-28-2000	Beretta	
NR	A3*	US-20020193295-A1	12-19-2002	Calenoff <i>et al.</i>	
NR	A4*	US-20030211510-A1	11-13-2003	Henderson <i>et al.</i>	
NR	A5*	US-6,649,166	11-18-2003	Maillere <i>et al.</i>	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
NR	B1	WO-00/44887	08-03-2000	Commissariat Energie Atomique <i>et al.</i>	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the iFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
NR	C1	Akdis <i>et al.</i> , "Epitope-Specific T Cell Tolerance to Phospholipase A(2) in Bee Venom Immunotherapy and Recovery by IL-2 and IL-15 in Vitro," <i>J. Clin. Invest.</i> , 98:1676-83, 1996.		
NR	C2	Akdis <i>et al.</i> , "Role of Interleukin 10 in Specific Immunotherapy," <i>J. Clin. Invest.</i> , 102:98-106, 1998.		
NR	C3	Bauer <i>et al.</i> , "Modulation of the Allergic Immune Response in BALB/c Mice by Subcutaneous Injection of High Doses of the Dominant T Cell Epitope from the Major Birch Pollen Allergen Bet v 1," <i>Clin. Exp. Immunol.</i> , 107:536-41, 1997.		
NR	C4	Briner <i>et al.</i> , "Peripheral T-Cell Tolerance Induced in Naive and Primed Mice by Subcutaneous Injection of Peptides from the Major Cat Allergen Fel d 1," <i>Proc. Natl. Acad. Sci. USA</i> , 90:7608-12, 1993.		
NR	C5	Casari <i>et al.</i> , "A Method to Predict Functional Residues in Proteins," <i>Structural Biology</i> , 2(2):171-178, February 1995.		
NR	C6	De Waal <i>et al.</i> , "Direct Effects of IL-10 on Subsets of Human CD4+ T Cell Clones and Resting T Cells. Specific Inhibition of IL-2 Production and Proliferation," <i>J. Immunol.</i> , 150:4754-65, 1993.		
NR	C7	Ferreira <i>et al.</i> , "Dissection of Immunoglobulin E and T Lymphocyte Reactivity of Isoforms of the Major Birch Pollen Allergen Bet v 1: Potential Use of Hypoallergenic Isoforms for Immunotherapy," <i>J. Exp. Med.</i> , 183:559-609, February 1996.		
NR	C8	Ferreira <i>et al.</i> , "Modulation of IgE Reactivity of Allergens by Site-Directed Mutagenesis: Potential Use of Hypoallergenic Variants for Immunotherapy," <i>The FASEB Journal</i> , 12:231-242, February 1998.		

Examiner Signature	/Nora Rooney/	Date Considered	02/02/2007
-----------------------	---------------	--------------------	------------

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/799,514-Conf. #8487	
			Filing Date	March 12, 2004	
			First Named Inventor	Francois Spertini	
			Art Unit	1644	
			Examiner Name	Not Yet Assigned	
Sheet	2	of	3	Attorney Docket Number	30985/41486

NR	C9	Groux <i>et al.</i> , "Interleukin-10 Induces a Long-Term Antigen-Specific Anergic State in Human CD4+ T Cells," <i>J. Exp. Med.</i> , 184:19-29, 1996.	
NR	C10	Hansen <i>et al.</i> , "Allergen-Specific Th1 Cells Fail to Counterbalance Th2 Cell-Induced Airway Hyperreactivity but Cause Severe Airway Inflammation," <i>J. Clin. Invest.</i> 103:175-83, 1999.	
NR	C11	Haselden, <i>et al.</i> , "Immunoglobulin E-Independent Major Histocompatibility Complex-Restricted T Cell Peptide Epitope-Induced Late Asthmatic Reactions," <i>J. Exp. Med.</i> , 189:1885-94, 1999.	
NR	C12	Hoynes <i>et al.</i> , "Regulation of House Dust Mite Responses by Intranasally Administered Peptide: Transient Activation of CD4+ T Cells Precedes the Development of Tolerance in Vivo," <i>Int. Immunol.</i> , 8:335-42, 1996.	
	C13	International Preliminary Report on Patentability from PCT/IB04/01300 dated October 10, 2004.	
	C14	International Search Report from PCT/IB04/01300 dated October 4, 2004.	
NR	C15	Jutel, <i>et al.</i> , "Selective Restimulation of Antigen or Allergen Preactivated T Cells Using OKT3 F(ab)(2) Results in the Secretion of TH-1 or TH-2-Like Cytokine Patterns," <i>Clin. Experiment. Allergy</i> , 25:1108-17, 1995.	
NR	C16	Kettner, <i>et al.</i> , "IgE and T-Cell Responses to High-Molecular Weight Allergens from Bee Venom," <i>Clin. Experiment. Allergy</i> , 29:394-401, 1999.	
NR	C17	King <i>et al.</i> , "Antibody Responses to Bee Melittin (Api m 4) and Hornet Antigen 5 (Dol m 5) in Mice Treated with the Dominant T-Cell Epitope Peptides," <i>J. Allerg. Clin. Immunol.</i> , 101:397-403, 1998.	
NR	C18	Larche, "Allergen-Derived T Cell Peptides in Immunotherapy," <i>Revue Francaise D'Allergologie et D'Immunologie Clinique 2003 France</i> , 43(1):59-63, 2003.	
NR	C19	Larche, "Peptide-Based Therapeutic Vaccines for Allergic and Autoimmune Diseases," <i>Nat. Med.</i> , 11(4 Suppl):S69-76, 2005.	
NR	C20	Laver <i>et al.</i> , "Epitopes on Protein Antigens: Misconceptions and Realities," <i>Cell</i> , 61:553-556, May 1990.	
NR	C21	Lesourd <i>et al.</i> , "Hymenoptera Venom Immunotherapy: Relationships with Specific Antibody Responses," <i>J. Allergy Clin. Immunol.</i> , 83:563-71, 1989.	
NR	C22	Malvey <i>et al.</i> , "Peripheral Immune Tolerance Blocks Clonal Expansion but Fails to Prevent the Differentiation of Th1 Cells," <i>J. Immunol.</i> , 161:2168-77, 1998.	
NR	C23	Mueller, "Diagnosis and Treatment of Insect Sensitivity," <i>J. Asthma Res.</i> , 3:331-3, 1966.	
NR	C24	Müller <i>et al.</i> , "Immunotherapy with Honeybee Venom and Yellow Jacket Venom is Different Regarding Efficacy and Safety," <i>J. Allergy Clin. Immunol.</i> , 89:529-35, 1992.	
NR	C25	Müller, <i>Insect Sting Allergy: Clinical Picture, Diagnosis and Treatment</i> , Stuttgart, New York:1990.	
NR	C26	Müller <i>et al.</i> , "Position Paper: Immunotherapy with Hymenoptera Venoms," <i>Allergy</i> , 48(Suppl. 14):37-46, 1993.	
NR	C27	Müller <i>et al.</i> , "Predictive Value of Venom-Specific IgE, IgG and IgG Subclass Antibodies in Patients on Immunotherapy with Honey Bee Venom," <i>Allergy</i> , 44:412-8, 1989.	
NR	C28	Müller <i>et al.</i> , "Type I Skin Reactivity to Native and Recombinant Phospholipase A(2) from Honeybee Venom is Similar," <i>J. Allerg. Clin. Immunol.</i> , 96:395-402, 1995.	
NR	C29	Norman <i>et al.</i> , "Treatment of Cat Allergy with T-Cell Reactive Peptides," <i>Am. J. Respir. Crit. Care Med.</i> , 154:1623-8, 1996.	

Examiner Signature	/Nora Rooney/	Date Considered	02/02/2007
--------------------	---------------	-----------------	------------

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/799,514-Conf. #8487
				Filing Date	March 12, 2004
				First Named Inventor	Francois Spertini
				Art Unit	1644
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	30985/41486

NR	C30	Oldfield, <i>et al.</i> , "Allergen-Derived T Cell Peptide-Induced Late Asthmatic Reactions Precede the Induction of Antigen-Specific Hyporesponsiveness in Atopic Allergic Asthmatic Subjects," <i>J. Immunol.</i> , 167:1734-9, 2001.	
NR	C31	Ollert <i>et al.</i> , "Prognostic Value of Immunoblotting in Patients on Immunotherapy with Hymenoptera Venom," <i>J. Allergy Clin. Immunol.</i> , 105:S59, Abstract 178, 2000.	
NR	C32	Pape, <i>et al.</i> , "Direct Evidence that Functionally Impaired CD4+ T Cells Persist in Vivo Following Induction of Peripheral Tolerance," <i>J. Immunol.</i> , 160:4719-29, 1998.	
NR	C33	Punnonen, "Molecular Breeding of Allergy Vaccines and Antiallergic Cytokines," <i>International Archives of Allergy and Immunology</i> , 121(3):173-182, 2000.	
NR	C34	Roggero <i>et al.</i> , "A Simple and Rapid Procedure for the Purification of Synthetic Polypeptides by a Combination of Affinity Chromatography and Methionine Chemistry," <i>FEBS Letters</i> , 408:285-8, 1997.	
NR	C35	Rueff <i>et al.</i> , "Ultrarush Immunotherapy in Patients with Hymenoptera Venom Allergy," <i>J. Allergy Clin. Immunol.</i> , 107:928-9, 2001.	
NR	C36	Schneider <i>et al.</i> , "Human Monoclonal or Polyclonal Antibodies Recognize Predominantly Discontinuous Epitopes on Bee Venom Phospholipase A ₂ ," <i>J. Allergy Clin. Immunol.</i> , 94(1):61-70, July 1994.	
NR	C37	Smith <i>et al.</i> , "Recombinant Allergens for Immunotherapy: A Der p2 Variant with Reduced IgE Reactivity Retains T-Cell Epitopes," <i>J. Allergy Clin. Immunol.</i> , 101(3):423-425, 1998.	
NR	C38	Takai <i>et al.</i> , "Engineering of the Major House Dust Mite Allergen Der f 2 for Allergen-Specific Immunotherapy," <i>Nature Biotechnology</i> , 15:754-758, August 1997.	
NR	C39	Tsitoura <i>et al.</i> , "Intranasal Exposure to Protein Antigen Induces Immunological Tolerance Mediated by Functionally Disabled CD4+ T Cells," <i>J. Immunol.</i> , 163:2592-600, 1999.	
NR	C40	Urbanek <i>et al.</i> , "Sub-Class of IgG Anti-Bee Venom Antibody Produced During Bee Venom Immunotherapy and Its Relationship to Long-Term Protection from Bee Stings and Following Termination of Venom Immunotherapy," <i>Clin. Allergy</i> , 16:317-22, 1986.	
NR	C41	Van Neerven <i>et al.</i> , "Characterization of Cat Dander-Specific T Lymphocytes from Atopic Patients," <i>J. Immunol.</i> , 152:4203-10, 1994.	
NR	C42	Van Neerven <i>et al.</i> , "T Cell Epitopes of House Dust Mite Major Allergen Der p II," <i>J. Immunol.</i> , 151:2326-35, 1993.	
NR	C43	Van Regenmortel, "Structural and Functional Approaches to the Study of Protein Antigenicity," <i>Immunology Today</i> , 10(8):266-272, 1989.	
	C44	Written Opinion from PCT/IB04/01300 dated October 4, 2004	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.


Examiner Signature	/Nora Rooney/	Date Considered	02/02/2007
-----------------------	---------------	--------------------	------------

Express Mail No.: EV 392131232 US
Date of Deposit: July 26, 2004

Page 1 of 1
Attorney Docket No.: 25720-502

Please type a plus sign (+) in this box

+



Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/799,514
	Filing Date	March 12, 2004
	First Named Inventor	Spertini
	Group Art Unit	1644
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	25720-502

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
NR	C16	Astori, et al., <i>J. Immunol.</i> , 165:3497-3505 (2000).
NR	C17	Fellarth, et al., <i>J. Allergy Clin. Immunol.</i> , 111:854-861 (2003).
NR	C18	Jilek, et al., <i>J. Immunol.</i> , 166:3612-3621 (2001).
NR	C19	Kettner, et al., <i>J. Allergy Clin. Immunol.</i> , 107:914-920 (2001).
NR	C20	Spertini, et al., Abstract Basel presented at the Swiss Society for Immunology, Basel, April 6-7 2000, and published in <i>Allergologie</i> , 23/3. 2000, p.156.
NR	C21	Spertini, et al., Abstract Berlin presented at EAACI (Eur. Acad. Allergy Clin. Immunol.) Congress, Berlin, May 9-13 2001, and published in <i>Allergy</i> , 56(suppl. 68):38.
NR	C22	Spertini, et al., Abstract ICACI Sydney presented at the XVII ICACI (Int. Congress Allergol. Clin. Immunol.) Sydney, Aus., 15-20 October, 2000, and published in <i>Allergy and Clin. Immunol. Int.</i>
NR	C23	Spertini, et al., Abstract AAAI presented at AAAI (Am. Acad. Allergy Asthma and Immunol.) San Diego, March 3-8, 2000, and published in <i>J. Allergy Clin. Immunol.</i> , 105(1 - pt. 2):S278.
NR	C24	Von Garnier, et al., <i>Eur. J. Immunol.</i> , 30:1638-1645 (2000).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Nora Rooney/	Date Considered	02/02/2007
--------------------	---------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

JUN 22 2004

Please type a plus sign (+) in this box

+

Modified Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/799,514
Filing Date	03/12/04
First Named Inventor	Spertini
Group Art Unit	1644
Examiner Name	Not Yet Assigned
Attorney Docket Number	25720-502

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
NR	A1	4,473,495	09/25/84	Patterson	260	112 R	
NR	A2	5,124,249	06/23/92	Khan, et al.	435	7.5	
NR	A3	5,152,980	10/06/92	Strom, et al.	424	85.2	
NR	A4	5,723,582	03/03/98	Ishizaka	530	351	
NR	A5	5,965,709	10/12/99	Presta, et al.	530	387.3	
NR	A6	6,074,673	06/13/00	Gullien	424	501	
NR	A7	6,395,306 B1	05/28/02	Cui, et al.	424	539	

U.S. PUBLISHED APPLICATION DOCUMENTS

Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
NR	A8	2003/0165514 A1	09/04/03	Spertini	424	185.1	
NR	A9	2004/0023291 A1	02/05/04	Spertini	435	7.1	

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
NR	B1	WO	93/19178	IMMUNOLOGIC PHARMACEUTICAL CORPORATION	09/30/93		
NR	B2	WO	99/18983	ALK-ABELLO	04/22/99		
NR	B3	WO	00/15774	PAN PACIFIC PHARMACEUTICALS, INC.	03/23/00		
NR	B4	WO	01/88085 A2	ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE EPFL-SRI	11/22/01		
NR	B5	GB	2 341 389 A	PAN PACIFIC PHARMACEUTICALS, INC.	03/15/00		

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
NR	C1	Akdis, et al., <i>FASEB J.</i> , 13:603-609 (1999).
NR	C2	Attwood, T. K., <i>Science</i> , 290(5491):471-473 (2000).
NR	C3	Banks, et al., in Plek T, ed., <i>Venoms of the Hymenoptera</i> , London: Academic Press, pages 329-416 (1986).
NR	C4	Burks, et al., <i>Eur. J. Biochem.</i> , 245:334-339 (1997).
NR	C5	Colman, in <i>A Structural View of Immune Recognition by Antibodies</i> , Biomolecular Research Institute, (Australia) pages 33-35.
NR	C6	Fasler, et al., <i>J. Allergy Clin. Immunol.</i> , 101(4 pt 1):521-530 (1998).

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
NR	C7	Jutel, et al., <i>J. Immunol.</i> , 154:41874194 (1995).
NR	C8	Kämmerer, et al., <i>J. Allergy Clin Immunol.</i> , 100(1):96-103 (1997).
NR	C9	Kämmerer, et al., <i>Clin. Exper. Allergy</i> , 27:1016-1026 (1997).
NR	C10	Müller, et al., <i>J. Allergy Clin. Immunol.</i> , 101:747-754 (1998).
NR	C11	Ngo et al., in <u>The Protein Folding Problem and Tertiary Structure Prediction</u> , Merz, et al., (ed.), Birkhäuser, Boston, MA, pp. 433 and 492-495 (1994).
NR	C12	Secrist, et al., <i>J. Exp. Med.</i> , 178:2123-2130 (1993).
NR	C13	Skolnick, et al., <i>Trends in Biotech.</i> , 18(1):34-38 (2000).
NR	C14	Stanley, et al., <i>Arch. Biochem. Biophys.</i> , 342(2):244-253 (1997).
NR	C15	Swoboda, et al., <i>J. Biol. Chem.</i> , 270(6):26072613 (1995).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Nora Rooney/	Date Considered	02/02/2007
--------------------	---------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.